Hepatitis Monthly

Published by: Kowsar

A Real-Life Study of New Antiviral Therapies in a High Prevalence Geographical Area for Hepatitis C Virus Infection

Alessandro Federico 1 , * , Marcello Dallio 1 , Giuseppe Gerardo Caprio 1 , Ilario de Sio 1 , Gaetano Cotticelli 1 , Pasquale Esposito 1 and Carmelina Loguercio 1
Authors Information
1 Hepatogastroenterology Division, University of Campania "L. Vanvitelli", Naples, Italy
Article information
  • Hepatitis Monthly: October 2018, 18 (10); e74224
  • Published Online: October 15, 2018
  • Article Type: Research Article
  • Received: May 2, 2018
  • Revised: August 11, 2018
  • Accepted: August 13, 2018
  • DOI: 10.5812/hepatmon.74224

To Cite: Federico A, Dallio M, Caprio G G, de Sio I, Cotticelli G, et al. A Real-Life Study of New Antiviral Therapies in a High Prevalence Geographical Area for Hepatitis C Virus Infection, Hepat Mon. 2018 ; 18(10):e74224. doi: 10.5812/hepatmon.74224.

Abstract
Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161-76. doi: 10.1016/S2468-1253(16)30181-9. [PubMed: 28404132].
  • 2. European Union HCV Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: A modelling study. Lancet Gastroenterol Hepatol. 2017;2(5):325-36. doi: 10.1016/S2468-1253(17)30045-6. [PubMed: 28397696].
  • 3. La Torre G, Gualano MR, Semyonov L, Nicolotti N, Ricciardi W, Boccia A. Hepatitis C Virus infections trends in Italy, 1996-2006. Hepat Mon. 2011;11(11):895-900. doi: 10.5812/kowsar.1735143X.767. [PubMed: 22308154]. [PubMed Central: PMC3269058].
  • 4. Marascio N, Liberto M, Barreca G, Zicca E, Quirino A, Lamberti A, et al. Update on epidemiology of HCV in Italy: Focus on the Calabria Region. BMC Infect Dis. 2014;14 Suppl 5. S2. doi: 10.1186/1471-2334-14-S5-S2. [PubMed: 25236184]. [PubMed Central: PMC4160896].
  • 5. Mennini FS, Marcellusi A, Andreoni M, Gasbarrini A, Salomone S, Craxi A. Health policy model: Long-term predictive results associated with the management of hepatitis C virus-induced diseases in Italy. Clinicoecon Outcomes Res. 2014;6:303-10. doi: 10.2147/CEOR.S62092. [PubMed: 24971024]. [PubMed Central: PMC4069043].
  • 6. Perrone V, Sangiorgi D, Buda S, Degli Esposti L. Disease progression and health care resource consumption in patients affected by hepatitis C virus in real practice setting. Clinicoecon Outcomes Res. 2016;8:591-7. doi: 10.2147/CEOR.S108288. [PubMed: 27789966]. [PubMed Central: PMC5072570].
  • 7. Buonomo AR, Scotto R, Pinchera B, Coppola N, Monari C, Macera M, et al. Epidemiology and risk factors for hepatitis C virus genotypes in a high prevalence region in Italy. New Microbiol. 2018;41(1):26-9. [PubMed: 29112765].
  • 8. Coppola N, Pisaturo M, Tonziello G, Sagnelli C, Sagnelli E, Angelillo IF. Efficacy of Pegylated Interferon alpha-2a and alpha-2b in patients with genotype 1 chronic hepatitis C: A meta-analysis. BMC Infect Dis. 2012;12:357. doi: 10.1186/1471-2334-12-357. [PubMed: 23245594]. [PubMed Central: PMC3556138].
  • 9. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver D. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology. 2009;49(4):1335-74. doi: 10.1002/hep.22759. [PubMed: 19330875].
  • 10. Loguercio C, Federico A, Masarone M, Torella R, Blanco Cdel V, Persico M. The impact of diet on liver fibrosis and on response to Interferon therapy in patients with HCV-related chronic hepatitis. Am J Gastroenterol. 2008;103(12):3159-66. doi: 10.1111/j.1572-0241.2008.02159.x. [PubMed: 18786125].
  • 11. Federico A, Masarone M, Romano M, Dallio M, Rosato V, Persico M. Rapid virological response represents the highest prediction factor of response to antiviral treatment in HCV-related chronic hepatitis: A multicenter retrospective study. Hepat Mon. 2015;15(6). e18640. doi: 10.5812/hepatmon.15(6)2015.18640. [PubMed: 26286149]. [PubMed Central: PMC4532787].
  • 12. Poordad F, McCone JJ, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195-206. doi: 10.1056/NEJMoa1010494. [PubMed: 21449783]. [PubMed Central: PMC3766849].
  • 13. Federico A, Sgambato D, Cotticelli G, Gravina AG, Dallio M, Beneduce F, et al. Skin adverse events during dual and triple therapy for HCV-related cirrhosis. Hepat Mon. 2014;14(3). e16632. doi: 10.5812/hepatmon.16632. [PubMed: 24734094]. [PubMed Central: PMC3984470].
  • 14. European Association for Study of Liver. EASL clinical practice guidelines: Management of hepatitis C virus infection. J Hepatol. 2014;60(2):392-420. doi: 10.1016/j.jhep.2013.11.003. [PubMed: 24331294].
  • 15. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867-77. doi: 10.1056/NEJMoa1214854. [PubMed: 23607593].
  • 16. Kondili LA, Romano F, Rolli FR, Ruggeri M, Rosato S, Brunetto MR, et al. Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort. Hepatology. 2017;66(6):1814-25. doi: 10.1002/hep.29399. [PubMed: 28741307]. [PubMed Central: PMC5765396].
  • 17. Grimaldi E, Della Pepa ME, Martora F, Magliocca P, Iovene MR, Coppola N, et al. Distribution of hepatitis C virus genotypes and subtypes in the metropolitan area of naples, Italy, in the era of Interferon-free regimens. Intervirol. 2017;60(3):82-9. doi: 10.1159/000481821. [PubMed: 29161710].
  • 18. Hutchison C, Kwong A, Ray S, Struble K, Swan T, Miller V. Accelerating drug development through collaboration: The Hepatitis C Drug Development Advisory Group. Clin Pharmacol Ther. 2014;96(2):162-5. doi: 10.1038/clpt.2014.113. [PubMed: 24853733].
  • 19. Lontok E, Harrington P, Howe A, Kieffer T, Lennerstrand J, Lenz O, et al. Hepatitis C virus drug resistance-associated substitutions: State of the art summary. Hepatol. 2015;62(5):1623-32. doi: 10.1002/hep.27934. [PubMed: 26095927].
  • 20. European Association for Study of L. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. [PubMed: 25911336].
  • 21. Li DK, Chung RT. Impact of hepatitis C virus eradication on hepatocellular carcinogenesis. Cancer. 2015;121(17):2874-82. doi: 10.1002/cncr.29528. [PubMed: 26079399]. [PubMed Central: PMC4545677].
  • 22. Scott N, Stoove M, Wilson DP, Keiser O, El-Hayek C, Doyle J, et al. Eliminating hepatitis C virus as a public health threat among HIV-positive men who have sex with men: A multi-modelling approach to understand differences in sexual risk behaviour. J Int AIDS Soc. 2018;21(1). doi: 10.1002/jia2.25059. [PubMed: 29314670]. [PubMed Central: PMC5810343].
  • 23. Asselah T, Marcellin P, Schinazi RF. Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure? Liver Int. 2018;38 Suppl 1:7-13. doi: 10.1111/liv.13673. [PubMed: 29427484].
  • 24. Cooper CL, Hatashita H, Corsi DJ, Parmar P, Corrin R, Garber G. Direct-acting antiviral therapy outcomes in canadian chronic hepatitis C telemedicine patients. Ann Hepatol. 2017;16(6):874-80. doi: 10.5604/01.3001.0010.5277. [PubMed: 29055923].
  • 25. Monllor-Nunell MT, Sanchez-Lloansi M, Dosal-Galguera A. Direct antiviral treatment in patients with hepatitis C virus: Implementation of a nurse telephone consultation. Enferm Clin. 2017;27(6):387-91. doi: 10.1016/j.enfcli.2017.09.005. [PubMed: 29074167].
  • 26. Lawitz E, Makara M, Akarca US, Thuluvath PJ, Preotescu LL, Varunok P, et al. Efficacy and safety of ombitasvir, paritaprevir, and ritonavir in an open-label study of patients with genotype 1b chronic hepatitis C virus infection with and without cirrhosis. Gastroenterol. 2015;149(4):971-80 e1. doi: 10.1053/j.gastro.2015.07.001. [PubMed: 26170136].
  • 27. Roeder C, Jordan S, Schulze Zur Wiesch J, Pfeiffer-Vornkahl H, Hueppe D, Mauss S, et al. Age-related differences in response to peginterferon alfa-2a/Ribavirin in patients with chronic hepatitis C infection. World J Gastroenterol. 2014;20(31):10984-93. doi: 10.3748/wjg.v20.i31.10984. [PubMed: 25152602]. [PubMed Central: PMC4138479].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments